Trial Profile

An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danusertib (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Sponsors Nerviano Medical Sciences

Most Recent Events

01 Apr 2022 This trial has been completed in France (End Date: 21 Sep 2009) according to European Clinical Trials Database record.
29 Sep 2009 Actual end date (Sep 2010) and actual number of patients (7) added as reported by ClinicalTrials.gov.
29 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com